Sai Parenterals Limited has informed the Exchange regarding a press release dated May 23, 2026, titled "Investors Press Release on the Standalone & Consolidated Audited financialresults for the quarter and year ended 31.03.2026.".
SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Parenterals reported exceptional Q4 FY26 results with revenue of ₹197.93 Cr (up 166.65% YoY), EBITDA of ₹28.97 Cr (up 366.79%) and PAT of ₹13.25 Cr (up 736.08%). Full year FY26 revenue stood at ₹380.99 Cr, up 140.37% YoY, with EBITDA at ₹47.21 Cr and PAT at ₹14.37 Cr. The strong growth was driven by CDMO exports (up 250%+ YoY), consolidation of newly acquired Australian subsidiary Noumed (74.6% stake acquired Nov 2025), and a portfolio of 88 new product dossiers added in FY26. The company also completed its IPO in March 2026 raising ₹285 Cr. Management guided FY27 revenue target of ₹750 Cr and EBITDA margins of 17% (vs 12.39% in FY26), with 67 dossiers in pipeline for commercialization.
The results show strong operating leverage with PAT margins expanding to 6.70% in Q4 from 2.14% YoY. The FY27 guidance of 17% EBITDA margins signals margin expansion ahead, which is positive for shareholders. The company's capex program of ~₹440 Cr for capacity expansion and new R&D centre positions it for sustained growth.